http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2020270908-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_067a3c5fff599aa564fefd4d03be8fde
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb9c6b40161bafe7bd55f0b4defcea04
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
filingDate 2020-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24a84725554a4eaaf8ee51ba946d0902
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7257aa5510be3a25c5c7bc06fb3524e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50c4ec19ef9620aca73c10965c5705e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d83632c901ff8893876aeafc1c24952
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffae7ad79039ab6b2211e6fd205d2b86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bea513d93a4390c06a12109fc332017b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c464661d2ed4536f51b957da5dd94ea
publicationDate 2021-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AU-2020270908-A1
titleOfInvention Degradation of AKT by conjugation of ATP-competitive AKT inhibitor GDC-0068 with E3 ligase ligands and methods of use
abstract Disclosed are bifunctional compounds comprising a GDC-0068 analog that binds AKT isoforms AKT1, 2 and 3, pharmaceutical compositions, and methods for treating diseases or conditions mediated by dysfunctional AKT activity.
priorityDate 2019-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465673843
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468129589
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468116355
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467380712
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468091281

Total number of triples: 32.